Table 1.
Characteristics of the Study Patients Before and After Propensity Score Matching
| Before Propensity Matching | After Propensity Matching | |||||
|---|---|---|---|---|---|---|
| Supportive Therapy (n=27) | Chemotherapy* (n=39) | P | Supportive Therapy (n=23) | Chemotherapy*(n=23) | P | |
| Age (year) (n (%)) | ||||||
| <60 | 11 (40.7%) | 21 (53.8%) | 0.295 | 9 (39.1%) | 12 (52.2%) | 0.375 |
| ≥60 | 16 (59.3%) | 18 (46.2%) | 14 (60.9%) | 11 (47.8%) | ||
| Gender (n (%)) | ||||||
| Male | 17 (63.0%) | 25 (64.1%) | 0.925 | 16 (69.6%) | 16 (69.6%) | 1.000 |
| Female | 10 (37.0%) | 14 (35.9%) | 7 (30.4%) | 7 (30.4%) | ||
| WBC (×109/L) (n (%)) | ||||||
| <13 | 14 (51.9%) | 16 (41.0%) | 0.385 | 14 (60.9%) | 11 (47.8%) | 0.375 |
| ≥13 | 13 (48.1%) | 23 (59.0%) | 9 (39.1%) | 12 (52.2%) | ||
| Hb (g/L) (mean±SD) | 72.137±17.861 | 74.936±19.078 | 0.550 | 74.522±16.393 | 75.891±21.510 | 0.809 |
| Neutrophil count (mean±SD) | 15.394±21.906 | 16.635±23.634 | 0.830 | 13.909±21.109 | 15.666±27.595 | 0.809 |
| Lymphocyte count (mean±SD) | 2.849±2.253 | 4.475±4.820 | 0.071 | 2.335±1.900 | 4.248±5.043 | 0.100 |
| Lymphocyte percent (%) (mean±SD) | 19.430±14.157 | 16.850±11.339 | 0.415 | 19.200±14.061 | 18.500±13.178 | 0.863 |
| PLT (×109/L) (mean±SD) | 90.963±123.101 | 165.869±269.059 | 0.182 | 88.217±132.352 | 133.213±132.528 | 0.255 |
| Albumin (g/L) (n (%)) | ||||||
| <30 | 8 (29.6%) | 4 (10.3%) | 0.045 | 5 (21.7%) | 4 (17.4%) | 0.710 |
| ≥30 | 19 (70.4%) | 35 (89.7%) | 18 (78.3%) | 19 (82.6%) | ||
| Blast cell percent (%) in PB (mean±SD) | 3.296±4.037 | 2.308±2.897 | 0.251 | 3.304±3.936 | 2.022±2.902 | 0.215 |
| Blast cell percent (%) in BM (mean±SD) | 9.370±7.038 | 8.564±4.685 | 0.578 | 8.261±5.045 | 7.891±4.426 | 0.793 |
| Bone marrow dysplasia in smear (n (%)) | ||||||
| Absent | 16 (59.3%) | 13 (33.3%) | 0.037 | 12 (52.2%) | 13 (56.2%) | 0.767 |
| Single/multi-lineage | 11 (40.7%) | 26 (66.7%) | 11 (47.8%) | 10 (43.5%) | ||
| Megakaryocyte dysplasia in smear (n (%)) | ||||||
| Yes | 9 (33.3%) | 20 (51.3%) | 0.149 | 9 (39.1%) | 10 (43.5%) | 0.765 |
| No | 18 (66.7%) | 19 (48.7%) | 14 (60.9%) | 13 (56.2%) | ||
| Bone marrow dysplasia in biopsy (n (%)) | ||||||
| Absent | 13 (48.1%) | 19 (48.7%) | 0.964 | 12 (52.2%) | 14 (60.9%) | 0.552 |
| Single/multi-lineage | 14 (51.9%) | 20 (51.3%) | 11 (47.8%) | 9 (39.1%) | ||
| WHO (n (%)) | ||||||
| CMML-0 | 5 (18.5%) | 4 (10.3%) | 0.313 | 4 (17.4%) | 2 (8.7%) | 0.312 |
| CMML-1 | 9 (33.3%) | 20 (51.3%) | 8 (34.8%) | 13 (56.2%) | ||
| CMML-2 | 13 (48.1%) | 15 (38.5%) | 11 (47.8%) | 8 (34.8%) | ||
| Chromosome karyotype (n (%)) | ||||||
| Normal | 13 (48.1%) | 31 (79.5%) | 0.138 | 14 (60.9%) | 17 (73.9%) | 0.345 |
| Abnormal | 10 (37.0%) | 8 (20.5%) | 9 (39.1%) | 6 (26.1%) | ||
| CPSS (n (%)) | ||||||
| Low | 7 (25.9%) | 17 (43.6%) | 0.392 | 6 (26.1%) | 9 (39.1%) | 0.586 |
| Intermediate-1 | 10 (37.0%) | 14 (35.9%) | 9 (39.1%) | 9 (39.1%) | ||
| Intermediate-2 | 9 (33.3%) | 7 (17.9%) | 7 (30.4%) | 5 (21.7%) | ||
| High | 1 (3.7%) | 1 (2.6%) | 1 (4.3%) | 0 (0%) | ||
Notes: Data are presented as mean±SD or n/N (%). *Chemotherapy group included patients underwent Hematopoietic Stem Cell Transplantation (HSCT).
Abbreviations: WBC, white blood cell; Hb, hemoglobin; PLT, platelet count; CPSS, CMML-specific Prognostic Scoring System; PB, Peripheral blood; BM, bone marrow.